How Biotech Startups Use Induced Pluripotent Stem Cells

In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging induced pluripotent stem cells (iPSCs) to revolutionize drug discovery and personalized medicine. They dive into the story of one startup—Fate Therapeutics—which uses iPSCs to create off-the-shelf cancer immunotherapies, and discuss the technical breakthroughs and business challenges that come with reprogramming adult cells into any cell type. Lucas breaks down the key advantage: iPSCs eliminate the need for embryonic stem cells and allow for mass production of standardized cells for therapies. Luna questions the scalability and cost hurdles, especially around manufacturing consistency and regulatory approval. The episode anchors on a 2025 milestone where a biotech startup, using iPSC-derived natural killer cells, reported a 70% response rate in a Phase 1 trial for relapsed lymphoma. The conversation also touches on the broader implications for neurodegenerative diseases and organ regeneration. If you're curious about how cellular reprogramming is moving from academic labs to commercial pipelines, this episode offers a clear, specific look at the science and the business. #InducedPluripotentStemCells #iPSCs #FateTherapeutics #CellTherapy #DrugDiscovery #BiotechStartups #CancerImmunotherapy #NaturalKillerCells #RegenerativeMedicine #PersonalizedMedicine #StemCells #Biotech #Business #Technology #FexingoBusiness #BusinessPodcast #LifeSciences #FDAApprovals Keep every episode free: buymeacoffee.com/fexingo